Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Six-Factor Stratification Approach for Enfortumab Vedotin Treatment in Previously Treated Patients with Advanced Urothelial Carcinoma

  • By

  • Yuto Matsushita

  • Satoru Taguchi

  • Taku Naiki

  • Gaku Ishikawa

  • Yu Nakamura

  • Jimpei Miyakawa

  • Takashi Nagai

  • Tomoyuki Kaneko

  • Hiroki Kubota

  • Hayato Hoshina

  • Jun Kamei

  • Aya Niimi

  • Yuta Yamada

  • Daisuke Obinata

  • Shigenori Kakutani

  • Masashi Shiozaki

  • Kento Ozawa

  • Michio Noda

  • Daichi Hirata

  • Yuichi Kitagawa

  • Yukihiro Yoshimi

  • Nozomi Sugiyama

  • Nobuhiko Shimizu

  • Yohei Tsubouchi

  • Keigo Sato

  • Kosuke Uchida

  • Shinya Watanabe

  • Jun Takahashi

  • Toshiharu Morikawa

  • Yoichi Mori

  • Takashi Murata

  • Taro Murata

  • Taketo Kawai

  • Takehiro Tanaka

  • Yukari Uemura

  • Tappei Takada

  • Sayuri Takahashi

  • Toshiki Ito

  • Masao Nagata

  • Hideyo Miyazaki

  • Satoshi Kurokawa

  • Yukio Yamada

  • Ryo Sato

  • Atsushi Otsuka

  • Yusuke Sato

  • Hiroaki Nishimatsu

  • Yukihiro Umemoto

  • Hiroshi Furuse

  • Yoshiyuki Akiyama

  • Yutaka Enomoto

  • Satoru Takahashi

  • Tetsuya Fujimura

  • Tohru Nakagawa

  • Hiroshi Fukuhara

  • Takahiro Yasui

  • Haruki Kume

  • Teruo Inamoto

  • September 11, 2026

Share

Clinical Scorecard: A Six-Factor Stratification Approach for Enfortumab Vedotin Treatment in Previously Treated Patients with Advanced Urothelial Carcinoma

At a Glance

CategoryDetail
ConditionAdvanced Urothelial Carcinoma
Key MechanismsEnfortumab vedotin (EV) monotherapy shows oncological benefit over standard chemotherapy.
Target PopulationPatients with locally advanced or metastatic urothelial carcinoma who have received prior systemic therapies.
Care SettingMulticenter retrospective investigation

Key Highlights

  • Median overall survival (OS) was 14.6 months.
  • Median progression-free survival (PFS) was 7.6 months.
  • Six common prognostic factors identified for PFS and OS.
  • Poor ECOG performance status is a significant prognostic factor.
  • Anemia and elevated CRP levels are associated with worse outcomes.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of advanced urothelial carcinoma confirmed through clinical and laboratory findings.

Management

  • Enfortumab vedotin is endorsed as an effective later-line treatment.

Monitoring & Follow-up

  • Monitor progression-free survival and overall survival post-treatment.

Risks

  • Consider risks associated with poor ECOG performance status, aberrant histology, and elevated inflammatory markers.

Patient & Prescribing Data

387 patients with advanced urothelial carcinoma treated with EV monotherapy.

Prior systemic therapies included a median of two, with a significant portion having received cisplatin-based regimens.

Clinical Best Practices

  • Utilize a stratification approach based on identified prognostic factors for treatment planning.
  • Assess laboratory findings such as hemoglobin levels and CRP for prognostic evaluation.
  • Implement regular monitoring of performance status and disease progression.

Related Resources & Content

Original Source(s)

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma

  • by Yuto Matsushita, Satoru Taguchi, Taku Naiki, Gaku Ishikawa, Yu Nakamura, Jimpei Miyakawa, Takashi Nagai, Tomoyuki Kaneko, Hiroki Kubota, Hayato Hoshina, Jun Kamei, Aya Niimi, Yuta Yamada, Daisuke Obinata, Shigenori Kakutani, Masashi Shiozaki, Kento Ozawa, Michio Noda, Daichi Hirata, Yuichi Kitagawa, Yukihiro Yoshimi, Nozomi Sugiyama, Nobuhiko Shimizu, Yohei Tsubouchi, Keigo Sato, Kosuke Uchida, Shinya Watanabe, Jun Takahashi, Toshiharu Morikawa, Yoichi Mori, Takashi Murata, Taro Murata, Taketo Kawai, Takehiro Tanaka, Yukari Uemura, Tappei Takada, Sayuri Takahashi, Toshiki Ito, Masao Nagata, Hideyo Miyazaki, Satoshi Kurokawa, Yukio Yamada, Ryo Sato, Atsushi Otsuka, Yusuke Sato, Hiroaki Nishimatsu, Yukihiro Umemoto, Hiroshi Furuse, Yoshiyuki Akiyama, Yutaka Enomoto, Satoru Takahashi, Tetsuya Fujimura, Tohru Nakagawa, Hiroshi Fukuhara, Takahiro Yasui, Haruki Kume, Teruo Inamoto

  • September 11, 2026

Related Content

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers

Case Report: Donor-derived early T-cell precursor acute lymphoblastic leukemia following an allogeneic hematopoietic stem cell transplantation for pediatric severe aplastic anemia